Guest Naveen Pemmaraju, MD, talks about the challenges and novel agents being explored in BPDCN. The podcast discusses the BPD-CN international registry, advancements in diagnosis and treatment, and the importance of multidisciplinary teams and improved communication.

Experts discuss the challenges of sequencing BCMA therapies in multiple myeloma, the prognostic value of circulating tumor cells, and the growing role of quadruplet therapies. They explore optimal combinations and sequencing, the Perseus trial comparing DARA VRD and VRD treatments, and the use of Dara KRD for newly diagnosed myeloma patients.

Leading experts Rabi Hanna, MD and Josu de la Fuente, PhD discuss key updates in sickle cell disease at ASH 2023. They cover topics such as disease biology, ongoing trials, and the growing role of gene therapy. They explore novel agents, pathogenesis, and potential therapies, highlighting improvements in natural history, mortality rates, and access to healthcare. The speakers also discuss advancements in treatment, including the reduction in vasoclecive events and hospitalizations, and the paradigm shift towards increasing fetal hemoglobin for management.

Experts Ashutosh Wechalekar and Vaishali Sanchorawala discuss updates in the diagnosis and treatment of amyloidosis at the 65th ASH Annual Meeting. They cover topics such as a new diagnostic test, the use of Bellantabap as a therapy, the safety and efficacy of Biltamimab, and the differences between staging systems for amyloidosis.

Ruben Mesa, a leading expert in the treatment of myeloproliferative neoplasms, and other experts discuss the exciting advances in the treatment of BCR-ABL1-negative MPNs at the ASH 2023 conference. Topics include ongoing clinical trials and novel agents in ET, PV, and MF, as well as the risk of disease transformation in young patients. They also explore effective therapies for myelofibrosis and express excitement for the future of MPN research.

Dr. David Maloney and Dr. Jason Westin discuss the role of CAR-T therapy in NHL, exploring alternative antigens and off-the-shelf options for treatment. They also explore the long-term outcomes and risks of CAR-T therapy, focusing on patient quality of life and the need for data on late toxicities.

Key highlights from the iwCLL 2023 conference include discussions on the role of continuous BTK inhibitors in CLL treatment, the biology of Richter's transformation, and the underrepresentation of elderly patients in clinical trials for CLL. Experts share insights on continuous therapy, drawbacks and advantages of BTK inhibitors, and the need for further research. The importance of including elderly patients in trials and comprehensive geriatric assessments is also emphasized.

Tanya Siddiqi and Nirav Shah discuss the role of BTK inhibitors and degraders in NHL. They also explore the growing role of bispecific antibodies in this disease setting. Topics include novel therapies, Perdibrutnib as a non-covalent inhibitor, lessons from a first-in-class bispecific therapy, potential of Biennium-2-M-Amp in DLBCL, and Phase 2 trial findings of Audra Nextermat and Plimotumab.

Guests Angela Dispenzieri, MD, Paolo Lopedote, MD, and Vaishali Sanchorawala, MD discuss unmet needs in AL amyloidosis, including early diagnosis and optimal treatment strategies. They explore the prevalence and impact of CHIP in amyloidosis patients, as well as alternative treatment options for those who cannot undergo stem cell transplantation. The speakers also discuss refining hematologic response criteria and assessing residual disease in AL amyloidosis treatment.

John Gribben and Laurie Sehn discuss the use of antibody-drug conjugates (ADCs) in NHL. They explore challenges in comparing treatment options, modulation of target antigen, and FDA's changing requirements for drug approval. Recent updates in the use of ADCs, including decreased accelerated approvals and the importance of efficacy and safety, are also highlighted.